GlobeNewswire · Press release
| Range | 6M |
|---|---|
| First date | — |
| Last date | — |
| Open | — |
| High | — |
| Low | — |
| Close | — |
| Volume | — |
| Plotted bars | 0 |
Event records
Event records load after the price chart.
Healthcare · Biotechnology
The Quantellect read. Short interest is 3.40% of float with a 6.05% borrow fee. Six active firms cover the stock as of Nov 19, 2026; three active firms with targets average $2.67 over 12 months. Descriptive summary of the data on this page, not a recommendation.
—
—
—
FINRA settlement Oct 30, 2026
Price — · As of —
| Range | 6M |
|---|---|
| First date | — |
| Last date | — |
| Open | — |
| High | — |
| Low | — |
| Close | — |
| Volume | — |
| Plotted bars | 0 |
Event records load after the price chart.
| Range | 6M |
|---|---|
| First close | — |
| Last close | — |
| High | — |
| Low | — |
| Volume | — |
RVPH · nasdaq · USD
Last completed session: Nov 17, 2026
Split-adjusted · volume in shares
— · Notable price movement not available
— · Options flow not available
Insufficient data · Tide session Nov 18, 2026
— · Industry comparison not available
Buy
Based on 6 active firms as of Nov 19, 2026 (365-day activity window)
As of Nov 19, 2026 across 3 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →— · Smart-money activity not available
All smart-money activity →GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity
Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.